News Column

Study Data from A. Latorre and Colleagues Update Understanding of Nanoparticles (DNA and aptamer stabilized gold nanoparticles for targeted delivery...

September 9, 2014



Study Data from A. Latorre and Colleagues Update Understanding of Nanoparticles (DNA and aptamer stabilized gold nanoparticles for targeted delivery of anticancer therapeutics)

By a News Reporter-Staff News Editor at Cancer Weekly -- Current study results on Nanoparticles have been published. According to news reporting from Madrid, Spain, by NewsRx journalists, research stated, "Gold nanoparticles (GNPs) can be used as carriers of a variety of therapeutics. Ideally, drugs are released in the target cells in response to cell specific intracellular triggers."

The news correspondents obtained a quote from the research, "In this study, GNPs are loaded with doxorubicin or AZD8055, using a self-immolative linker which facilitates the release of anticancer therapeutics in malignant cells without modifications of the active compound. An additional modification with the aptamer AS1411 further increases the selectivity of GNPs towards cancer cells. Both modifications increase targeted delivery of therapeutics with GNPs. Whereas GNPs without anticancer drugs do not affect cell viability in all cells tested, AS1411 modified GNPs loaded with doxorubicin or AZD8055 show significant and increased reduction of cell viability in breast cancer and uveal melanoma cell lines."

According to the news reporters, the research concluded: "These results highlight that modified GNPs can be functionalized to increase the efficacy of cancer therapeutics and may further reduce toxicity by increasing targeted delivery towards malignant cells."

For more information on this research see: DNA and aptamer stabilized gold nanoparticles for targeted delivery of anticancer therapeutics. Nanoscale, 2014;6(13):7436-42. (Royal Society of Chemistry - www.rsc.org/; Nanoscale - pubs.rsc.org/en/journals/journalissues/nr)

Our news journalists report that additional information may be obtained by contacting A. Latorre, Instituto Madrileno de Estudios Avanzados en Nanociencia, CNB-CSIC-IMDEA Nanociencia Associated Unit, Cantoblanco, Madrid, Spain. Additional authors for this research include C. Posch, Y. Garcimartin, A. Celli, M. Sanlorenzo, I. Vujic, J. Ma, M. Zekhtser, K. Rappersberger, S. Ortiz-Urda and A Somoza (see also Nanoparticles).

Keywords for this news article include: Madrid, Spain, Europe, Cancer, Emerging Technologies, Nanoparticle, Nanoparticles, Nanotechnology, Oncology.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters